arrow
O

Ola Nilsson

Karolinska University Hospital
H指数:78
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genome sequencing and clinical diagnosis in 186 pediatric and adult patients with genetic skeletal disorders

对186例患有遗传性骨骼疾病的儿童和成人患者的基因组测序与临床诊断

2026-01-010
OA
EndoCompass Project: Research Roadmap for Growth Disorders

EndoCompass项目:生长障碍研究路线图

2025-12-010
OA
EndoCompass project: research roadmap for growth disorders

EndoCompass项目:生长障碍的研究路线图

2025-10-010
PRE
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis
2024-05-182
OAAI
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period

Burosumab与X连锁低磷血症患儿的常规治疗: 开放标签,3期延长期的结果

2024-01-043
OAAI
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
2023-09-2717
OAAI
Real-world evidence in achondroplasia: considerations for a standardized data set

软骨发育不全的真实世界证据: 标准化数据集的考虑

2023-06-264
OAAI
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level

Burosumab与磷酸盐/活性维生素d在小儿X连锁低磷血症中的作用: 剂量水平的亚组分析

2023-04-219
OA
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-Linked hypophosphataemia: rationale and description
2022-09-056
OAAI
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia

与常规疗法相比,Burosumab对X连锁低磷血症的年龄较小和年龄较大的儿童的影响

2022-05-0945
OA